Spain, the UK and the US). GlobalData is the parent company of Pharmaceutical Technology. "AbbVie enters obesity space with $2.3bn Gubra deal" was originally created and published by ...

AbbVie has submitted its oral CGRP inhibitor ... by 2030 in the five major European markets of France, Germany, Italy, Spain, and the UK. Atogepant was approved last September as Qulipta for ...

AbbVie has secured its fourth FDA approval for ... the five largest European markets (France, Germany, Italy, Spain, and the UK), plus Japan and Canada, although it noted competition is growing ...